Efficacy of Palivizumab Prophylaxis Among Infants With Congenital Heart Disease: A Case Control Study

Ozyurt A., NARİN N., BAYKAN A., Argun M., PAMUKÇU Ö., ZARARSIZ G., ...Daha Fazla

PEDIATRIC PULMONOLOGY, cilt.50, sa.10, ss.1025-1032, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 50 Sayı: 10
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1002/ppul.23102
  • Dergi Adı: PEDIATRIC PULMONOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1025-1032
  • Anahtar Kelimeler: clinical trials, congenital heart disease, palivizumab prophylaxis, lower respiratory tract infections, RSV, hospitalization, risk factors, RESPIRATORY SYNCYTIAL VIRUS, HIGH-RISK CHILDREN, COST-EFFECTIVENESS, YOUNG-CHILDREN, INFECTION, PREVENTION, IMPACT
  • Erciyes Üniversitesi Adresli: Evet

Özet

Background: Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey.